Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Liquidia Q3 2026 Results: Net Loss of $236M, Loss Widens

Liquidia Corp is a non-accelerated filer focused on the commercialization of YUTREPIA and the development of L606 for pulmonary hypertension. As of October 28, 2026, the company reported 90,106,442 shares of common stock outstanding and is navigating ongoing legal settlements and regulatory filings with the FDA.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue225.354.3
Profit before tax-266.4-3.5
Net income-236.3-3.5
EPS (diluted, $ a share)$-2.64$-0.04

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+314.6%
Operating margin-117.0%
Source

10-Q filed with the SEC, NASDAQ: LQDA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Liquidia Corp: key numbers

Share price
$56.37Close, Nov 16
Market cap
$5.08B
Shares outstanding
90.11MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Liquidia Corp

All →
7:01 AM ET 8-K
Financial Results

Liquidia Financial Results

Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.

Term
Q3 2026

“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer
4:32 PM ET Form 4
Insider Selling

Liquidia CAO Dana Boyle Sells $68.3K of Stock

Dana Boyle, CAO, sold 1,581 shares of Liquidia Corp at $43.19 a share, worth $68.3K in total on Oct 26, 2026. Shares held after the trade: 164,028 (-1.0%).

Value
$68.3K
Shares
1,581
Price
$43.19
Role
CAO
Holding change
-1.0%
Trade date
Oct 26, 2026
4:31 PM ET Form 4
Insider Selling

Liquidia Chief Business Officer Jason Adair Sells $29.7K of Stock

Jason Adair, Chief Business Officer, sold 688 shares of Liquidia Corp at $43.19 a share, worth $29.7K in total on Oct 26, 2026. Shares held after the trade: 177,269 (-0.4%).

Value
$29.7K
Shares
688
Price
$43.19
Role
Chief Business Officer
Holding change
-0.4%
Trade date
Oct 26, 2026
6:03 AM ET 8-K
Court & Legal Update

Liquidia Court & Legal Update

Liquidia Corporation entered into a global settlement agreement with United Therapeutics to resolve all ongoing patent infringement, trade secret, and antitrust litigation. Liquidia will make aggregate payments of $320.4 million to UTC ($175M net initial payment plus $145.4M in 2027 installments) while agreeing to remove the PH-ILD indication from its YUTREPIA label to maintain the product's availability for PAH patients.

Counterparty
United Therapeutics Corporation

“Today’s agreement fully resolves years of litigation and provides certainty to PAH patients that they can continue to access YUTREPIA, whose differentiated attributes have enabled its rapid adoption by physicians and patients since launch.”

Dr. Roger Jeffs, CEO
8:05 PM ET Form 4
Insider Selling

Liquidia General Counsel Russell Schundler Sells $390K of Stock

Russell Schundler, General Counsel, sold 13,692 shares of Liquidia Corp at $28.48 a share, worth $390K in total on Oct 12, 2026. Shares held after the trade: 602,841 (-2.2%).

Value
$390K
Shares
13,692
Price
$28.48
Role
General Counsel
Holding change
-2.2%
Trade date
Oct 12, 2026
8:04 PM ET Form 4
Insider Selling

Liquidia CMO Rajeev Saggar Sells $263K of Stock

Rajeev Saggar, CMO, sold 9,218 shares of Liquidia Corp at $28.48 a share, worth $263K in total on Oct 12, 2026. Shares held after the trade: 126,368 (-6.8%).

Value
$263K
Shares
9,218
Price
$28.48
Role
CMO
Holding change
-6.8%
Trade date
Oct 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.